Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bowler

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Pathology|January 1, 1991
Corticotropin deficiency: a rare cause of hyponatremia mimicking SIADHE A De Leacy, S Bowler, J M Brown, et al.
The European Respiratory Journal|June 1, 2007
Daily versus weekly azithromycin in cystic fibrosis patientsJ McCormack, S Bell, S Senini, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|September 10, 2011
Characterization of the liver kinase B1-mouse protein-25 -Ste-20-related adaptor protein complex in adult mouse skeletal muscleCody D Smith, Richard A Compton, Joshua S Bowler, et al.
Genomics|April 7, 1999
An integrated physical and gene map of human distal chromosome 17q24-proximal 17q25 encompassing multiple disease lociL M Kalikin, R A George, M P Keller, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 1, 1997
Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstructionC F McDonald, R J Pierce, P J Thompson, et al.
HIV Research & Clinical Practice|February 5, 2020
Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapyS Bowler, C Siriwardhana, B I Mitchell, et al.
Internal Medicine Journal|June 29, 2016
Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair RegistryP G Gibson, H Reddel, V M McDonald, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 6, 2016
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteriaM Hew, A Gillman, M Sutherland, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Pathology|January 1, 1991
Corticotropin deficiency: a rare cause of hyponatremia mimicking SIADHE A De Leacy, S Bowler, J M Brown, et al.
The European Respiratory Journal|June 1, 2007
Daily versus weekly azithromycin in cystic fibrosis patientsJ McCormack, S Bell, S Senini, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|September 10, 2011
Characterization of the liver kinase B1-mouse protein-25 -Ste-20-related adaptor protein complex in adult mouse skeletal muscleCody D Smith, Richard A Compton, Joshua S Bowler, et al.
Genomics|April 7, 1999
An integrated physical and gene map of human distal chromosome 17q24-proximal 17q25 encompassing multiple disease lociL M Kalikin, R A George, M P Keller, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|January 1, 1997
Comparison of oral bambuterol and terbutaline in elderly patients with chronic reversible airflow obstructionC F McDonald, R J Pierce, P J Thompson, et al.
HIV Research & Clinical Practice|February 5, 2020
Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapyS Bowler, C Siriwardhana, B I Mitchell, et al.
Internal Medicine Journal|June 29, 2016
Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair RegistryP G Gibson, H Reddel, V M McDonald, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|July 6, 2016
Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteriaM Hew, A Gillman, M Sutherland, et al.
Pageof 3